No title
Introduction: Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson’s disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa–carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa–entaca
